Market Place
Sourcing Support
DeepCure Presents Ex Vivo Data For DC-9476 At ACR Convergence
24 Oct 2024 //
BUSINESSWIRE
Biora Therapeutics Presents Phase 1 Data For BT-600 At KOL Event
18 Jul 2024 //
GLOBENEWSWIRE
Biora To Host KOL Event On NaviCap Platform And BT-600 Trial Results
08 Jul 2024 //
GLOBENEWSWIRE
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
01 Jul 2024 //
GLOBENEWSWIRE
Aurobindo `s Generic Betamethasone Dipropionate Receives Approval in the U.S
04 Jun 2024 //
FDA
Organovo Shows FXR314 IBD Combination Potential At DDW2024
21 May 2024 //
GLOBENEWSWIRE
Prinston Pharma`s Generic Tofacitinib Receives Tentative Approval in U.S
09 Apr 2024 //
FDA
Teva Pharma`s Generic Tofacitinib Receives Approval in the U.S.
02 Feb 2024 //
FDA
CCSB obtained US patent for Tofacitinib Citrate
11 Jan 2024 //
PRESS RELEASE
Sinotherapeutics` Generic Tofacitinib Receives Approval in the U.S.
08 Aug 2023 //
FDA
Zydus Lifesciences gets USFDA nod for Tofacitinib tablets
22 Mar 2023 //
CNBCTV18
FDA Confirms Paragraph IV Patent Litigation for Tofacitinib Tablets
21 Mar 2023 //
FDA
Zydus` Generic Tofacitinib Citrate Receives Approval in the U.S.
14 Mar 2023 //
FDA
Vyne swings behind BET, seeks partner for failed eczema drug
10 Mar 2023 //
FIERCE BIOTECH
MSN`s Generic Tofacitinib Citrate Receives Approval in the U.S.
06 Jan 2023 //
FDA
EMA backs restrictions on certain immune-regulating drugs
12 Nov 2022 //
BIOPHARMADIVE
JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC
01 Nov 2022 //
EUROPEANPHARMACEUTICALREVIEW
EMA limits use of JAK inhibitors for at-risk groups in wake of safety concerns
29 Oct 2022 //
ENDPTS
Tofacitinib shows promise in scleroderma patients, researchers optimistic
06 Oct 2022 //
LABBLOG
Biora, with spin on Xeljanz nearing the clinic, posts data
11 Jul 2022 //
FIERCEPHARMA
Crowded rheumatoid arthritis category gets JAK reality check, while TNF
21 Apr 2022 //
ENDPTS
EMA initiates safety review on JAK inhibitors; Galapagos woes continue
12 Feb 2022 //
ENDPTS
Bristol`s deucravacitinib not just another JAK drug, exec says
21 Jan 2022 //
FIERCEPHARMA
FDA Confirms Para IV Patent Challenge for Tofacitinib Oral Solution
11 Jan 2022 //
FDA
AbbVie`s Rinvoq, Pfizer`s Xeljanz nab JAK label expansions
16 Dec 2021 //
FIERCEPHARMA
FDA Approves Pfizer’s XELJANZ for Active Ankylosing Spondylitis
14 Dec 2021 //
BUSINESSWIRE
AbbVie`s Label for RINVOQ to Include Additional Cardiac Risk Info
04 Dec 2021 //
STREETINSIDER
Pfizer’s XELJANZ Receives MA in the EU for Active Ankylosing Spondylitis
18 Nov 2021 //
BUSINESSWIRE
Lilly touts Olumiant long-term safety data amid JAK mess
11 Nov 2021 //
FIERCEPHARMA
AbbVie CEO can`t confirm Rinvoq`s sales as FDA mulls JAK label
29 Oct 2021 //
FIERCEPHARMA
Pfizer snags eczema nod for Xeljanz follow-up JAK in UK first
11 Sep 2021 //
FIERCEPHARMA
NICE recommends Pfizer’s Xeljanz for juvenile idiopathic arthritis
10 Sep 2021 //
PHARMAFILE
Insurers to squeeze JAK inhibitor access in chronic conditions after FDA warning
09 Sep 2021 //
PHARMACEUTICAL-TECHNOLOGY
NICE recommends treatment for people with juvenile idiopathic arthritis
09 Sep 2021 //
NICE
Pfizer, Teva settle patent dispute over blockbuster arthritis drug Xeljanz
08 Sep 2021 //
BLOOMBERGLAW
AbbVie`s stock & next megablockbuster take hits post new JAK warnings from FDA
01 Sep 2021 //
ENDPTS
FDA warns of heart-related events, cancer, blood clot & death for JAK inhibitors
01 Sep 2021 //
ENDPTS
XELJANZ® Receives Marketing Authorization in the European Union
20 Aug 2021 //
BUSINESSWIRE
Pfizer’s Xeljanz shows lifesaving benefits in COVID-19
18 Jun 2021 //
FIERCEPHARMA
Data Published in NEJM Shows Pfizer’s Tofacitinib Positive Results
16 Jun 2021 //
BUSINESSWIRE
Incyte`s Jakafi falls victim to FDA`s JAK scrutiny
09 Jun 2021 //
FIERCEPHARMA
Ajanta Pharma Ltd`s Generic Tofacitinib Citrate Receives Approval In US
01 Jun 2021 //
FDA
FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz
10 Feb 2021 //
PMLIVE
FDA weighs tighter restrictions for Pfizer`s Xeljanz
05 Feb 2021 //
FIERCEPHARMA
Initial safety trial results find increased risk of serious heart problems
05 Feb 2021 //
FDA
Pfizer`s Xeljanz fails to match safety of TNF inhibitors in arthritis study
28 Jan 2021 //
ENDPTS
Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (tofacitinib)
06 Nov 2020 //
BUSINESSWIRE
Zydus Cadila receives US FDA tentative marketing approval for tofacitinib ER tab
19 Oct 2020 //
PHARMABIZ
Pfizer CEO slams "political rhetoric" around COVID-19 vaccine development
02 Oct 2020 //
FORBES
Pfizer’s Xeljanz receives US FDA approval to treat active polyarticular
30 Sep 2020 //
PHARMABIZ
FDA Approvals Roundup: Nucala, Fetroja, Xeljanz
30 Sep 2020 //
RAPS
FDA approves Pfizer`s Xeljanz for polyarticular course juvenile idiopathic
29 Sep 2020 //
SEEKING ALPHA
USFDA Approves XELJANZ® for the Treatment of Active Polyarticular Course JIA
29 Sep 2020 //
BIOSPACE
Ajanta Pharma Ltd`s Generic Tofacitinib Receives Tentative Approval In US
15 Sep 2020 //
FDA
ICER criticizes cost of 8 targeted immune modulators for UC
15 Sep 2020 //
ENDPOINTS
Top biotech analyst projects a gloomy outlook for Pfizer`s JAK portfolio
10 Jul 2020 //
ENDPTS
Pfizer’s immunology drugs could all be beaten by rivals: analyst
09 Jul 2020 //
FIERCE PHARMA
AI VIVO seeks pharma, biotech collaboration partners to advance drug candidates
10 May 2020 //
MEDICAL
Drugmakers from Pfizer to GSK to hike U.S. prices on over 200 drugs
01 Jan 2020 //
CNBC
AbbVie’s JAK inhibitor Rinvoq approved in EU for rheumatoid arthritis
20 Dec 2019 //
PMLIVE
